Περίληψη:
Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-generation antimicrotubuline inhibitor and is currently the only approved drug for secondline treatment across the European Union. We conducted a retrospective analysis assessing the efficacy and safety of vinflunine in 71 Greek patients with relapsed urothelial cancer who were treated between 2005 and 2014. An overall 84% of our patients received vinflunine as second-line treatment, 77% had a performance status of Eastern Cooperative Oncology Group scale 0 or 1, and 30% had liver metastasis at the time of vinflunine administration. A median of four cycles of vinflunine were administered (range 1-16). The most common reported adverse events were constipation, fatigue, and anemia. Median progression-free survival was 6.2 months (95% confidence interval: 4.4-8.8) and overall survival was 11.9 months (95% confidence interval: 7.4-21). Two patients (3%) achieved a complete remission, seven a partial remission (10%), and 22 (31%) had stable disease according to an intention-to-treat analysis. Hemoglobin level less than 10 g/dl and Eastern Cooperative Oncology Group performance status greater than 1 were independent adverse prognostic factors. Stratification according to the Bellmunt risk model was also associated with progression-free survival and overall survival in our population. Vinflunine appears to be a safe and effective treatment modality for relapsed urothelial cancer. More effective therapies and more accurate prognostic algorithms should be sought. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Συγγραφείς:
Pistamaltzian, N.
Tzannis, K.
Pissanidou, V.
Peroukidis, S.
Milaki, G.
Karavasilis, V.
Mitsogiannis, I.
Varkarakis, I.
Papatsoris, A.
Dellis, A.
Adamakis, I.
Stravodimos, K.
Molyva, D.
Athanasiadis, I.
Androulakis, N.
Andreadis, C.
Kalofonos, C.
Mitropoulos, D.
Deliveliotis, C.
Constantinides, C.
Dimopoulos, M.A.
Bamias, A.
Λέξεις-κλειδιά:
carboplatin; cisplatin; doxorubicin; gemcitabine; methotrexate; vinblastine; vinflunine; antineoplastic agent; tubulin modulator; vinblastine; vinflunine, aged; anemia; Article; bladder cancer; cancer adjuvant therapy; cancer prognosis; constipation; diarrhea; drug efficacy; drug safety; fatigue; female; heart disease; hemoglobin blood level; human; kidney disease; liver metastasis; major clinical study; male; nausea; neurotoxicity; neutropenia; overall survival; priority journal; progression free survival; retrospective study; thrombocytopenia; urothelial bladder cancer; vomiting; analogs and derivatives; middle aged; pathology; survival analysis; tumor recurrence; Urinary Bladder Neoplasms; urothelium, Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Tubulin Modulators; Urinary Bladder Neoplasms; Urothelium; Vinblastine
